Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 92

1.

Desmosterol in human nonalcoholic steatohepatitis.

Simonen M, Männistö V, Leppänen J, Kaminska D, Kärjä V, Venesmaa S, Käkelä P, Kuusisto J, Gylling H, Laakso M, Pihlajamäki J.

Hepatology. 2013 Sep;58(3):976-82. doi: 10.1002/hep.26342. Epub 2013 Jul 29.

PMID:
23447451
2.

Serum interleukin 1 receptor antagonist as an independent marker of non-alcoholic steatohepatitis in humans.

Pihlajamäki J, Kuulasmaa T, Kaminska D, Simonen M, Kärjä V, Grönlund S, Käkelä P, Pääkkönen M, Kainulainen S, Punnonen K, Kuusisto J, Gylling H, Laakso M.

J Hepatol. 2012 Mar;56(3):663-70. doi: 10.1016/j.jhep.2011.10.005. Epub 2011 Oct 23.

PMID:
22027586
3.

Fatty liver disease: predictors of nonalcoholic steatohepatitis and gallbladder disease in morbid obesity.

Liew PL, Lee WJ, Wang W, Lee YC, Chen WY, Fang CL, Huang MT.

Obes Surg. 2008 Jul;18(7):847-53. doi: 10.1007/s11695-007-9355-0. Epub 2008 May 6.

PMID:
18459024
4.

Prevalence and associated metabolic factors of fatty liver disease in the elderly.

Wang Z, Xu M, Peng J, Jiang L, Hu Z, Wang H, Zhou S, Zhou R, Hultström M, Lai EY.

Exp Gerontol. 2013 Aug;48(8):705-9. doi: 10.1016/j.exger.2013.05.059. Epub 2013 May 27.

PMID:
23721951
5.

Free fatty acids repress small heterodimer partner (SHP) activation and adiponectin counteracts bile acid-induced liver injury in superobese patients with nonalcoholic steatohepatitis.

Bechmann LP, Kocabayoglu P, Sowa JP, Sydor S, Best J, Schlattjan M, Beilfuss A, Schmitt J, Hannivoort RA, Kilicarslan A, Rust C, Berr F, Tschopp O, Gerken G, Friedman SL, Geier A, Canbay A.

Hepatology. 2013 Apr;57(4):1394-406. doi: 10.1002/hep.26225.

PMID:
23299969
6.

[Clinical and histological features of non-alcoholic fatty liver disease].

Shi JP, Xun YH, Hu CB, Zhang L, Liu H, Lou GQ, Fan JG.

Zhonghua Gan Zang Bing Za Zhi. 2009 Nov;17(11):812-6. Chinese.

PMID:
19958638
7.

Hepatic steatosis in obese Chinese children.

Chan DF, Li AM, Chu WC, Chan MH, Wong EM, Liu EK, Chan IH, Yin J, Lam CW, Fok TF, Nelson EA.

Int J Obes Relat Metab Disord. 2004 Oct;28(10):1257-63.

PMID:
15278103
8.

Serum leptin levels in patients with nonalcoholic steatohepatitis.

Uygun A, Kadayifci A, Yesilova Z, Erdil A, Yaman H, Saka M, Deveci MS, Bagci S, Gulsen M, Karaeren N, Dagalp K.

Am J Gastroenterol. 2000 Dec;95(12):3584-9.

PMID:
11151896
9.

[Nonalcoholic steatohepatitis in obese children: the prevalence and possible mechanism].

Fu JF, Liang L, Wang CL, Hong F, Dong GP, Li Y.

Zhejiang Da Xue Xue Bao Yi Xue Ban. 2006 Jan;35(1):64-8. Chinese.

PMID:
16470923
10.

Hepatic histopathology of morbid obesity: concurrence of other forms of chronic liver disease.

Liew PL, Lee WJ, Lee YC, Wang HH, Wang W, Lin YC.

Obes Surg. 2006 Dec;16(12):1584-93.

PMID:
17217634
11.

Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels: a role for insulin resistance and diabetes.

Fracanzani AL, Valenti L, Bugianesi E, Andreoletti M, Colli A, Vanni E, Bertelli C, Fatta E, Bignamini D, Marchesini G, Fargion S.

Hepatology. 2008 Sep;48(3):792-8. doi: 10.1002/hep.22429.

PMID:
18752331
12.

Visceral adipose tissue and inflammation correlate with elevated liver tests in a cohort of overweight and obese patients.

Verrijken A, Francque S, Mertens I, Talloen M, Peiffer F, Van Gaal L.

Int J Obes (Lond). 2010 May;34(5):899-907. doi: 10.1038/ijo.2010.4. Epub 2010 Feb 9.

PMID:
20142825
13.

Presence and extent of estrogen receptor-alpha expression in patients with simple steatosis and NASH.

Erkan G, Yilmaz G, Konca Degertekin C, Akyol G, Ozenirler S.

Pathol Res Pract. 2013 Jul;209(7):429-32. doi: 10.1016/j.prp.2013.04.010. Epub 2013 May 2.

PMID:
23707549
14.

Nonalcoholic steatohepatitis (NASH) with diabetes: predictors of liver fibrosis.

Amarapurka DN, Amarapurkar AD, Patel ND, Agal S, Baigal R, Gupte P, Pramanik S.

Ann Hepatol. 2006 Jan-Mar;5(1):30-3.

PMID:
16531962
15.

Effect of exercise and dietary modification on serum aminotransferase levels in patients with nonalcoholic steatohepatitis.

Sreenivasa Baba C, Alexander G, Kalyani B, Pandey R, Rastogi S, Pandey A, Choudhuri G.

J Gastroenterol Hepatol. 2006 Jan;21(1 Pt 1):191-8.

PMID:
16706832
16.

Nonalcoholic fatty liver disease in severely obese subjects.

Gholam PM, Flancbaum L, Machan JT, Charney DA, Kotler DP.

Am J Gastroenterol. 2007 Feb;102(2):399-408.

PMID:
17311652
17.

Mitochondrial abnormality and oxidative stress in nonalcoholic steatohepatitis.

Kojima H, Sakurai S, Uemura M, Fukui H, Morimoto H, Tamagawa Y.

Alcohol Clin Exp Res. 2007 Jan;31(1 Suppl):S61-6.

PMID:
17331168
18.

Nonalcoholic steatohepatitis in nondiabetic obese patients.

Zamin I Jr, de Mattos AA, Zettler CG.

Can J Gastroenterol. 2002 May;16(5):303-7.

PMID:
12045779
19.

Fatty acid metabolism is altered in non-alcoholic steatohepatitis independent of obesity.

Walle P, Takkunen M, Männistö V, Vaittinen M, Lankinen M, Kärjä V, Käkelä P, Ågren J, Tiainen M, Schwab U, Kuusisto J, Laakso M, Pihlajamäki J.

Metabolism. 2016 May;65(5):655-66. doi: 10.1016/j.metabol.2016.01.011. Epub 2016 Jan 23.

PMID:
27085774
20.

Ketone body production is differentially altered in steatosis and non-alcoholic steatohepatitis in obese humans.

Männistö VT, Simonen M, Hyysalo J, Soininen P, Kangas AJ, Kaminska D, Matte AK, Venesmaa S, Käkelä P, Kärjä V, Arola J, Gylling H, Cederberg H, Kuusisto J, Laakso M, Yki-Järvinen H, Ala-Korpela M, Pihlajamäki J.

Liver Int. 2015 Jul;35(7):1853-61. doi: 10.1111/liv.12769. Epub 2015 Jan 20.

PMID:
25533197
Items per page

Supplemental Content

Write to the Help Desk